Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619242 · ClinicalTrials.gov registry record · NA
The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00619242: Clinical Trial NA study, sponsored by University of Chicago.
NCT00619242 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00619242, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.
Primary Outcome
Biomarker. Change in Ki-67 staining between pre- and on-therapy biopsies in patients with Barrett's esophagus.
Interventions
- DRUG sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-09 |
| Phase | NA |
Why NCT00619242 stopped before completion
NCT00619242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which sorafenib is the first listed.
NCT00619242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00619242 about?
NCT00619242 is a clinical study titled "The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer". To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.
What is the current status of trial NCT00619242?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2006-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00619242?
The interventions under investigation include: sorafenib (DRUG).
Who is sponsoring clinical trial NCT00619242?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00619242's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia